Skip to NavigationSkip to content

Shire and New River expect new ADHD launch in 2006

Published on 08/12/05 at 02:53pm

New River Pharmaceuticals has filed a new treatment for attention deficit hyperactivity disorder (ADHD) with US regulator the FDA.

New River signed a collaborative agreement to develop and commercialise NRP104 with UK-based Shire in January 2005 for the products development, manufacturing, marketing and sales in the US.

"The filing of NRP104 is excellent news for both Shire and New River," said Shire's chief executive Matthew Emmens. "We are pleased that this application has been submitted on schedule and we look forward to working with New River toward an approval and subsequent launch in 2006."

Once launched, Shire will book the product sales and New River may supply up to 25% of the sales effort under a co-promotion right. New River will be financially and operationally responsible for clinical and manufacturing development.







Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches